Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ASLAN Pharma Published Positive Phase I Data for It's Bone Loss Drug, ASLAN002

publication date: Feb 16, 2017
Science Translational Medicine, a peer-reviewed journal, has published new data from a Phase I study of ASLAN002 (BMS777607), ASLAN Pharmaceuticals’ small-molecule dual inhibitor of the cMET receptor tyrosine kinase and RON kinase. The data show that inhibition of RON reduces osteoclast bone absorption and indicate that RON signalling in the osteoclast is a new target for treating pathogenic bone loss in the settings of osteoporosis and bone lytic cancers such as breast, lung, prostate, kidney and thyroid. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital